secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001448431-25-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx posts Q3 net income of $0.8M, revenue up 22% to $26.1M; raises FY2025 outlook
--------------------------------------------------------------------------------

- Q3 revenue $26.1M (+22% YoY); GAAP net income $0.8M ($0.04/share) vs loss of $9.1M in Q3 2024.
- Adjusted EBITDA $5.1M (up from $2.7M); gross profit $17.5M (+30% YoY).
- Raised FY2025 guidance: revenue $105-109M, adjusted EBITDA $16-19M.
- Introduced FY2026 guidance: revenue $118-124M, adjusted EBITDA $19-22M.
- Cash $19.5M at Sep 30, 2025; paid $2M on term loan post-quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000144843125000018/0001448431-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000144843125000018/oprx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001448431-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer